Abcam, ab232933, Anti-TLR9 antibody [EPR21735] - BSA and Azide free

Size: 100µg / 1mg
Knockout Tested Rabbit Recombinant Monoclonal TLR9 antibody. Carrier free. Suitable for IP, WB and reacts with Human samples.
Key facts
Host species:Rabbit,
Clonality:Monoclonal,
Clone number:EPR21735,
Isotype:IgG,
Carrier free:Yes,
Reacts with:Human,
Applications:WB, IPSee reactivity dataSee the reactivity data table below for information on validated species and application combinations.,
Immunogen:The exact immunogen used to generate this antibody is proprietary information.

Product details:
ab232933 is the carrier-free version of
ab211012
Patented technology
Our RabMAb
technology is a patented hybridoma-based technology for making rabbit monoclonal antibodies. For details on our patents, please refer to
RabMAb® patents
What are the advantages of a recombinant monoclonal antibody?
This product is a recombinant monoclonal antibody, which offers several advantages including:
- High batch-to-batch consistency and reproducibility
- Improved sensitivity and specificity
- Long-term security of supply
- Animal-free batch production
For more information, read more on
recombinant antibodies
Conjugation ready
Our carrier-free antibodies are typically supplied in a PBS-only formulation, purified and free of BSA, sodium azide and glycerol. This conjugation-ready format is designed for use with fluorochromes, metal isotopes, oligonucleotides, and enzymes, which makes them ideal for antibody labelling, functional and cell-based assays, flow-based assays (e.g. mass cytometry) and Multiplex Imaging applications.
Use our
conjugation kits
for antibody conjugates that are ready-to-use in as little as 20 minutes with 1 minute hands-on-time and 100% antibody recovery: available for fluorescent dyes, HRP, biotin and gold.
Compatibility
This product is compatible with the Maxpar
Antibody Labeling Kit from Fluidigm, without the need for antibody preparation. Maxpar
is a trademark of Fluidigm Canada Inc.

Properties and Storage Information:
Form-Liquid, Purification technique-Affinity purification Protein A, Storage buffer-pH: 7.2 - 7.4Constituents: PBS, Shipped at conditions-Blue Ice, Appropriate short-term storage conditions-+4°C, Appropriate long-term storage conditions-+4°C, Storage information-Do Not Freeze

Supplementary Information:
This supplementary information is collated from multiple sources and compiled automatically.
TLR9 also known as Toll-like receptor 9 is a protein that detects unmethylated CpG motifs which are common in bacterial and viral DNA. This protein weighs about 116 kDa. It mainly expresses in plasmacytoid dendritic cells B cells and in epithelial cells of various tissues. TLR9 locates in the endoplasmic reticulum and translocates to endolysosomes upon activation which is essential for its detection function.
Biological function summary
TLR9 recognizes and binds to microbial DNA triggering an immune response. It is part of the Toll-like receptor family which plays an important role in the innate immune system. TLR9 engages in the formation of complexes with other molecules such as MyD88 an adaptor protein to propagate downstream signaling. This leads to the activation of transcription factors that stimulate cytokine production promoting inflammation and defense against infections.
Pathways
TLR9 participates significantly in the NF-kB activation pathway and the type I interferon signaling cascade. During these processes TLR9 interacts with proteins like IRAK4 and TRAF6. In the NF-kB pathway TLR9's role in the early immune response is coordinated with other Toll-like receptors to detect pathogen-related patterns and initiate adaptive immunity. Its influence on type I interferon signaling facilitates antiviral defense mechanisms.
TLR9's malfunction or altered expression associates with systemic lupus erythematosus (SLE) and cancer. In SLE overactivation of TLR9 leads to autoantibody production which worsens the disease. This can involve the protein BAFF which supports B cell proliferation. In cancer TLR9 can influence tumor growth and the tumor microenvironment affecting disease progression. Its modulation is being researched for therapeutic interventions in these conditions.